Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
12.68
+0.28 (2.22%)
At close: Sep 8, 2026, 4:00 PM EDT
12.75
+0.07 (0.59%)
After-hours: Sep 8, 2026, 7:59 PM EDT
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $39.66M in the quarter ending June 30, 2026, with 53.25% growth. This brings the company's revenue in the last twelve months to $136.07M, up 119.40% year-over-year. In the year 2025, Zevra Therapeutics had annual revenue of $106.47M with 350.91% growth.
Revenue (ttm)
$136.07M
Revenue Growth
+119.40%
P/S Ratio
5.53
Revenue / Employee
$2,230,672
Employees
61
Market Cap
752.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.47M | 82.86M | 350.91% |
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.00M | 162.58% |
| Dec 31, 2022 | 10.46M | -18.19M | -63.50% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | 12.84M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| Gyre Therapeutics | 109.82M |
| Verastem | 87.53M |
| Assembly Biosciences | 74.85M |
| Oculis Holding AG | 1.45M |
| Neurogene | 925.00K |
ZVRA News
- 6 days ago - Zevra Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - GlobeNewsWire
- 18 days ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 4 weeks ago - Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim - TheFly
- 4 weeks ago - Zevra Therapeutics price target raised to $28 from $25 at Citizens - TheFly
- 4 weeks ago - Zevra Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Zevra Therapeutics Earnings release: Q2 2026 - Filings